Biotech Toolmakers to Benefit from Obama
January 28, 2009
– Comments (4)
By all indications, the stimulus package being voted on today includes significant increases for NIH funding.
http://www.genomeweb.com/node/910396 (might require registration).
"The Federal economic stimulus package that awaits both Congress and newly-inaugurated President Barack Obama includes billions of dollars in new funding for the National Institutes of Health and other research agencies, as well as a major funding plan for a health information technology program.
The stimulus package, which currently is in the US House of Representatives, offers $3.5 billion to NIH, $460 million for renovation at the US Centers for Disease Control and Prevention, a total of $20 billion to back health information technology initiatives, and billions for other agencies that fund biomedical research and genomics, according to the House Ways and Means and Appropriations Committees.
...
In its current draft, the package seeks $1.5 billion to fund NIH research and $500 million to implement a repairs and improvement plan for NIH campuses. Another $1.5 billion in the bill would go through NIH to renovate university research facilities and “help them compete for biomedical research grants.”
NIH funding has seen only very modest funding increases over the past few years. Who benefits from this? Generally the pick and shovel providers of biotechnology, whose sales into the research committee are significantly influenced by levels of acedemic spending. Here is a list from an index maintained by GenomeWeb
ACCL Accelrys
AXK Accelr8
AFFX Affymetrix
A Agilent
BEC Beckman
BDX Becton Dickinson
BIO Bio-Rad
BRKR Bruker
CALP Caliper
CRA Celera
CPHD Cepheid
CLDA Clinical Data
CBMX CombiMatrix
CGEN Compugen
DCGN DeCode Genetics
GHDX Genomic Health
GPRO Gen-Probe
HLCS Helicos BioSciences
ILMN Illumina
LIFE Life Technologies
LMNX Luminex
MDZ MDS
MIL Millipore
MGRM Monogram Biosciences
MYGN Myriad Genetics
NGEN Nanogen
NSPH Nanosphere
ORCH Orchid Cellmark
PKI PerkinElmer
PBIO Pressure BioSciences
QGEN Qiagen
ROSG Rosetta Genomics
SQNM Sequenom
SIAL Sigma-Aldrich
TMO Thermo
WAT Waters
I have many of these in my CAPS port already, as I think this is the best way to invest in biotechnology (slow and steady rather than shoot for the moon). Time to add a few more. I want to keep my active picks ~50, so this is where I'll seek additions. Could be a time before these pay off though, and massive pharma cutbacks haven't helped the industry (though the outsourcing movement arguably does).
TMFHelical
Community Analyst Team
RSS Headlines
Fool UK